SCHEMBL22200601

SCHEMBL22200601

CC(C)n1c(=O)c(-c2ccc(NSc3ccccc3C#N)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.43
PIK3CD O00329 3/20 0.36
MTOR P42345 6/20 0.34
EGFR P00533 4/20 0.34
PRKDC P78527 4/20 0.34
ABL1 P00519 2/20 0.34
HCK P08631 2/20 0.34
SRC P12931 2/20 0.34
KDR P35968 2/20 0.34
PIK3CA P42336 2/20 0.34
PIK3CB P42338 2/20 0.34
PIK3CG P48736 2/20 0.34
EPHB4 P54760 2/20 0.34
CYP1A2 P05177 7/20 0.33
USP2 O75604 6/20 0.33
CYP3A4 P08684 5/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 3/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200350 0.88 USP2 (0.38) ERN1MTOREGFRSRCCYP1A2
SCHEMBL22200361 0.87 ERN1 (0.45) ERN1PIK3CDMTOREGFRPRKDC
SCHEMBL22200352 0.86 ERN1 (0.40) ERN1PIK3CDMTOREGFRCYP1A2
SCHEMBL25035356 0.84 ERN1 (0.49) ERN1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL25035545 0.82 ERN1 (0.59) ERN1PIK3CDCYP1A2USP2CYP3A4
SCHEMBL22200598 0.82 ERN1 (0.38) ERN1PIK3CDMTORCYP1A2USP2
SCHEMBL22200583 0.81 ERN1 (0.54) ERN1PIK3CDMTOREGFRPRKDC
SCHEMBL22200338 0.81 ERN1 (0.41) ERN1MTORCYP1A2USP2CYP3A4
SCHEMBL22200345 0.81 ERN1 (0.53) ERN1MTORCYP1A2USP2CYP3A4
SCHEMBL22200356 0.80 ERN1 (0.41) ERN1MTORPIK3CACYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed